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Alemtuzumab is an antibody directed against the Cluster of Differentiation (CD)52. It 
depletes B and T lymphocytes and is approved for treatment of active relapsing-
remitting multiple sclerosis (RRMS). Secondary autoimmunity is an important risk of 
alemtuzumab-treated patients and can affect different organs. 41% of patients develop 
autoimmune thyroid disease2. Skin autoimmunity under alemtuzumab has but 
reported only in the neurological literature3,4. 
We describe a 33-year-old male patient who developed hypopigmentation around his 
melanocytic nevi with disappearance of the nevi in August 2018. In June 2016 he had 
been diagnosed with highly active RRMS and treated with alemtuzumab in September 
2016 for the first time. In September 2017 another cycle of alemtuzumab was 
administered. The patient´s family history for vitiligo was unremarkable and he had 
no autoimmune thyroid disease. At time of the occurrence of the hypopigmented spots 
the number of his circulating leukocytes in the blood was normal. Upon examination 
he showed sharply demarcated hypopigmented spots around his melanocytic nevi 
(Fig. 1A). Some of the nevi within the white spots had already disappeared. There 
were no other signs of skin hypopigmentation. A biopsy specimen from one of the 
halo-like nevi (insert of Fig. 1A) revealed absence of epidermal melanocytes (Fig. 1B) 
which was confirmed by immunohistochemistry with an anti-Pan Mel antibody (Fig. 
1C). In contrast, melanocytes were detected within the nevus (Fig. 1C). 
Immunostaining with an anti-CD3 antibody disclosed a sparsely scattered infiltrate of 
T lymphocytes within the upper dermis (Fig. 1D, E). To shed light into the 
pathogenesis of the halo nevus-like lesions we wondered whether alemtuzumab might 
directly attack epidermal melanocytes. CD52 immunohistochemistry of normal skin 
and a melanocytic nevus from a healthy person did not show immunoreactivity in 
melanocytes in contrast to lymphoid tissues used as positive control (data not shown). 






























































Since autoimmune thyroid disease is characterized by circulating anti-thyroid 
antibodies, we hypothesized whether anti-melanocyte antibodies may be generated 
following alemtuzumab treatment. In patients with non-segmental vitiligo (NSV) 
antibodies against tyrosinase (TYR), the key enzyme of melanin synthesis, were also 
detected5. Therefore, a TnT® T7-Coupled Reticulocyte Lysate System (Promega, 
Southampton, UK) was used to produce various [35S]-labelled melanocyte antigens in 
vitro from the translation of cDNA in the appropriate plasmid. Serum samples of the 
patient before and after alemtuzumab therapy were then analysed for circulating 
antibodies against these antigens by radioligand binding assays5. An almost 6-fold 
increase in anti-TYR antibodies and a ~3-fold increase in antibodies against TYR-
related protein 1 were detected following alemtuzumab (Table 1). In contrast, anti-
thyroid antibodies were not detected throughout the patient´s history. In accordance 
with this TSH levels were always normal.
Our findings are puzzling as alemtuzumab depletes both B and T cells but still evokes 
an autoimmune attack against melanocytes. Recently, three patients with RRMS have 
been described who developed NSV 14, 18 and 52 months after initiation of 
alemtuzumab6. The immune-mediated destruction pathways of melanocytes in classic 
halo nevus and NSV may be different7. It has been suggested that secondary 
autoimmunity induced by alemtuzumab is related to proliferation of chronically 
activated, oligoclonal, effector memory CD8+ T cells8. Interestingly, resident and 
effector memory T cells have been identified in non-active skin of patients with 
NSV9. Previous studies showed that alemtuzumab depletes all T cells from the blood 
but does not deplete skin-resident memory T cells10. Thus, production of anti-
melanocyte-specific antibodies may be secondary to initial destruction of melanocytes 
by melanocyte-specific CD8+ T cells.






























































In summary, alemtuzumab-induced skin autoimmunity is a condition a dermatologist 
should be aware of. Our report underscores the complex pathogenesis of immune-
mediated destruction of epidermal melanocytes that may follow even upon depletion 
of both T and B cells.
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(A) Clinical appearance of the posterior trunk of the patient. The insert depicts the 
halo-like nevus from which the biopsy was taken; (B) Haematoxylin & eosin staining 
and (C) Pan Mel immunohistochemistry of the lesion (as shown in insert of Fig 1A). 
Note the absence of epidermal melanocytes; (D, E) CD3 immunostaining of the 
lesion. Note scattered T cells adjacent to the dermal melanocytes (D) and along the 
dermal-epidermal junction devoid of melanocytes (E).






























































Table 1: Presence of circulating anti-melanocyte antibodies in the patient’s serum 
before (Sept/2016) and after initiation of alemtuzumab (Aug/2018 and Feb/2019).
1Radioligand binding assays (RLBA) were used to test for antibodies against LMNA, 
laminA, TYR, tyrosinase; TYRP1, TYR-related protein 1; DCT, dopachrome 
tautomerase; PMEL, premelanosome protein; TH, tyrosine hydroxylase; and MCHR1, 
melanin-concentrating hormone receptor 1.
2An antibody index for the patient’s serum was calculated for each RLBA as: counts 
per min (cpm) immunoprecipitated by serum/mean cpm immunoprecipitated by 20 
healthy control sera. Positive antibody indices are in bold.
3The upper limit of normal for the RLBAs was calculated using the mean antibody 
index + 3 SD of the population of 20 healthy control sera. 




















LMNA 1.23 1.09 1.15 1.59
TYR 2.23 12.89 13.12 1.72
TYRP1 1.25 3.04 3.89 1.57
DCT 0.95 0.99 1.03 1.36
PMEL 1.14 1.26 1.19 1.45
TH 1.09 1.12 1.15 1.84
MCHR1 0.95 0.94 0.98 1.48































































(A) Clinical appearance of the posterior trunk of the patient. The insert depicts the halo-like nevus from 
which the biopsy was taken; (B) Haematoxylin & eosin staining and (C) Pan Mel immunohistochemistry of 
the lesion (as shown in insert of Fig 1A). Note the absence of epidermal melanocytes; (D, E) CD3 
immunostaining of the lesion. Note scattered T cells adjacent to the dermal melanocytes (D) and along the 
dermal-epidermal junction devoid of melanocytes (E). 
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